Partnerships and co-selling vs the traditional approach: what actually beats what for healthcare and life sciences in the DACH region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

The debate about partnerships and co-selling is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Partnerships and co-selling wins on speed of learning, targeting precision, and cost per outcome. It is using another company's distribution to reach buyers you cannot cost-effectively reach yourself, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first partnerships and co-selling attempt underperforms — they replace the wrong parts.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Combine them deliberately. Use partnerships and co-selling to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: sourced and influenced pipeline from partners, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is signing MOUs no one operationalises — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.